Accelerating the path to regulatory submission with RWD
The use of real-world data (RWD) in pharmaceutical development is becoming increasingly prevalent...
Rare diseases may be individually uncommon, but collectively they affect an estimated 30 million people in the United States. Yet for many patients, the path to diagnosis spans years, sometimes decades. Symptoms appear one at a time. Specialists...
The use of real-world data (RWD) in pharmaceutical development is becoming increasingly prevalent...
With the start of 2024, we are moving toward a world without third-party cookies to track consumer...
With recent disruptions in the availability of real-world data (RWD) for clinical research,...
While the CDC is considered the nation’s leading authority on infectious diseases, it is also...
With advances in artificial intelligence (AI) making headlines almost daily, the life sciences...
An interview with Kristijan Kahler, executive director of innovation evidence at Novartis While...
Given its role at the intersection of novel real-world data and emerging technologies, HealthVerity...
Our series on how Privacy Preserving Record Linkage (PPRL) technology can help government agencies...
HealthVerity is proud to partner with Inovalon, the largest closed claims data source in the U.S.,...
In our ongoing series on how Privacy-Preserving Record Linkage (PPRL) technology can help...
AI is playing a growing role in real-world evidence, but not all AI serves the same purpose. Two terms often used interchangeably, Generative AI and Agentic AI, describe very different capabilities and the distinction matters in real-world evidence (...